Skip to main content
Premium Trial:

Request an Annual Quote

GenomOncology, Vanderbilt-Ingram to Improve Genomic Tool for Cancer Management

NEW YORK (GenomeWeb News) – GenomOncology and Vanderbilt-Ingram Cancer Center today announced they are partnering to develop a new genomics content management tool that will enable actionable results directed at cancer more quickly.

The tool will be based on Vanderbilt-Ingram's My Cancer Genome and will be developed to enhance the knowledge resource to enable "automated interpretation of mutations in the genome of a patient's tumor, providing actionable results in hours versus days," GenomOncology and Vanderbilt-Ingram said. The website will remain free and open to the public.

In addition, commercial uses of My Cancer Genome will be licensed through GenomOncology, the partners said.

The knowledge resource was launched by Vanderbilt-Ingram in 2011 to help physicians and researchers keep abreast of developments in precision cancer medicine and connect with clinical research trials. Through the web-based tool, clinicians can get information on the "rapidly expanding list of genetic mutations that impact cancers," the partners said.

"A resource like My Cancer Genome that matches tumor mutations to therapies and makes information accessible and convenient is an incredibly valuable tool," GenomOncology President and CEO Manuel Glynias said in a statement. "Our collaboration with Vanderbilt-Ingram Cancer Center on My Cancer Genome is designed to keep this resource comprehensive, scalable, and easy for clinicians to use."